Education
About Us
Working with TipRanks
Follow Us
Pyxis Oncology (PYXS)
NASDAQ:PYXS
PYXS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.83 - $5.39
Previous CloseN/A
Volume258.73K
Average Volume (3M)427.30K
Market Cap
$81.77M
Enterprise Value$67.01M
Total Cash (Recent Filing)$126.93M
Total Debt (Recent Filing)$20.20M
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Aug 19, 2025EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding61,947,666
10 Day Avg. Volume352,791
30 Day Avg. Volume427,304
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.54
Price to Sales (P/S)0.00
P/FCF Ratio-1.15
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue0.90
Enterprise Value/Gross Profit4.80
Enterprise Value/Ebitda-0.26
Forecast
1Y Price Target
$6.83Price Target Upside450.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Pyxis Oncology News
PremiumCompany Announcements
Pyxis Oncology Reports Increased Losses Amidst Ongoing R&D Investments
PremiumCompany Announcements
Pyxis Oncology Reports Q1 Loss and Business Update
PremiumCompany Announcements
Pyxis Oncology Highlights Strategic Focus on Lead Candidate
Bulls Say, Bears Say
Bulls Say
Clinical ProgressMicvotabart pelidotin’s first-in-class, non-internalizing and stroma-targeted cytotoxic mechanism is viewed positively, particularly due to early Ph 1 dose escalation efficacy signals in SCCHN.
Strategic FocusThe assumption of CMO duties by CEO Lara Sullivan is seen as a strategic move to enhance focus and efficiency in clinical execution.
Therapeutic PotentialThere is sufficient biologic, preclinical, and clinical support to warrant outsized optimism for micvo’s therapeutic potential in SCCHN relative to other tested tumor types.
Bears Say
Clinical ChallengesMicvo's clinical profile might not be sufficient to impact the treatment paradigm in head and neck cancer, which is the current target indication.
Financial PerformanceNet loss of $21.2 million, or a loss of $0.35 per share, was comparable to the projected loss, indicating financial challenges.
Investor SentimentPYXS’s persistent underperformance and negative EV evidently reflects continued investor skepticism of micvo’s opportunity in SCCHN.
Ownership Overview
10.31% Insiders
6.38% Mutual Funds
25.01% Other Institutional Investors
50.79% Public Companies and Individual Investors
PYXS FAQ
What was Pyxis Oncology’s price range in the past 12 months?
Pyxis Oncology lowest stock price was $0.83 and its highest was $5.39 in the past 12 months.
What is Pyxis Oncology’s market cap?
Pyxis Oncology’s market cap is $81.77M.
When is Pyxis Oncology’s upcoming earnings report date?
Pyxis Oncology’s upcoming earnings report date is Aug 19, 2025 which is in 73 days.
How were Pyxis Oncology’s earnings last quarter?
Pyxis Oncology released its earnings results on May 15, 2025. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.294 by -$0.056.
Is Pyxis Oncology overvalued?
According to Wall Street analysts Pyxis Oncology’s price is currently Undervalued.
Does Pyxis Oncology pay dividends?
Pyxis Oncology does not currently pay dividends.
What is Pyxis Oncology’s EPS estimate?
Pyxis Oncology’s EPS estimate is -0.35.
How many shares outstanding does Pyxis Oncology have?
Pyxis Oncology has 61,947,666 shares outstanding.
What happened to Pyxis Oncology’s price movement after its last earnings report?
Pyxis Oncology reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.294. Following the earnings report the stock price went up 3.738%.
Which hedge fund is a major shareholder of Pyxis Oncology?
Currently, no hedge funds are holding shares in PYXS
Pyxis Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.83 (450.81% Upside)
$6.83 (450.81% Upside)
Blogger Sentiment
Bullish
PYXS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 218.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $174.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.93%
12-Months-Change
Fundamentals
Return on Equity
-66.30%
Trailing 12-Months
Asset Growth
-38.30%
Trailing 12-Months
Company Description
Pyxis Oncology
Pyxis Oncology, Inc. (PYXS) is a biopharmaceutical company focused on developing novel antibody-drug conjugates (ADCs) and immuno-oncology therapeutics for the treatment of cancer. The company operates within the healthcare sector, primarily targeting oncology as its core field. Pyxis Oncology aims to address unmet medical needs by leveraging its proprietary platforms to discover and develop innovative therapies that improve patient outcomes.
PYXS Stock 12 Month Forecast
Average Price Target
$6.83
▲(450.81%Upside)